Recall Timeline for “Sartan” Drugs

Since July 2018, the FDA has issued several recalls for valsartan, irbesartan, and losartan. This timeline outlines the recalls as well as FDA updates pertaining to valsartan, irbesartan, and losartan. If you or a loved one developed liver cancer, stomach/intestinal cancer, colorectal cancer, or kidney cancer after taking valsartan, losartan, or irbesartan, please fill out the contact form below.

The recall timeline for angiotension II receptor blockers

NDMA & NDEA: What’s the Difference?

In July 2018, the FDA recalled certain batches of valsartan after investigators found N-Nitrosimethylamine (NDMA) had contaminated the drug. Since then, several batches of valsartan, irbesartan, and losartan have been recalled due to NDMA and N-Nitrosodiethylamine (NDEA) contamination. These nitrosamines are classified as probable human carcinogens.

How Are They Similar?

NDMA and NDEA are both classified by the Environmental Protection Agency as probable human carcinogens. Exposure to these carcinogens can cause tumors to develop in the respiratory tract. Specifically, an individual may develop liver, kidney, stomach, colorectal, and/or intestinal cancer.

What’s the Difference?

The main difference between NDMA and NDEA is toxicity. NDEA happens to be about three times more toxic than NDMA.

What Should I Do?

If you or a loved one took a recalled valsartan, irbesartan, or losartan and developed liver, kidney, stomach, colorectal, or intestinal cancer, please fill out the form below. We deliver the Gold standard advocacy you deserve.

New Carcinogen Found in Losartan

On February 28, 2019, the FDA recalled 87 lots of losartan after finding trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA). NMBA is the third nitrosamine found in the angiotensin II receptor blocker (ARB) medicines valsartan, losartan, and irbesartan.  NDMA and NDEA, two other nitrosamines, were previously found in these drugs leading to numerous recalls.

Like NDMA and NDEA, NMBA is considered a probable human carcinogen. The FDA has concluded that the levels of NMBA found in the recalled lots are higher than the FDA’s interim acceptable intake limits. The nitrosamines found in the ARB medications can cause numerous types of cancer including liver cancer, kidney cancer, stomach cancer, and colorectal cancer.

The most recent recall includes lots from Camber Pharmaceuticals, Inc. The full list of recalled products can be found on the FDA’s website. If you or a loved one took a recalled product, contact your doctor before you stop taking the product.

GoldenbergLaw is currently accepting valsartan, irbesartan, and losartan cases in which an individual was diagnosed with liver, kidney, colorectal, or stomach cancer. Contact us for a free case consultation.